Adding Acetazolamide on Top of SGLT2 Inhibition in Persons With Type 2 Diabetes

Prior treatment

• Use of carbonic anhydrase inhibitor in the 30 days prior to screening
• Acute coronary syndrome, stroke or transient ischemic attack within 30 days prior to screening
• Participation in another drug trial within 30 days of screening

Other illness

• Established diagnosis of type 1 diabetes as per Diabetes Canada
• With known or suspected hypersensitivity or allergy to acetazolamide, dapagliflozin or related products
• Untreated urinary or genital tract infection
• Any other clinical condition that, based on Investigator's judgement, would jeopardize patient safety during trial participation or would affect the study outcome

Lab values

• Serum potassium \<3.5 mmol/L
• Serum bicarbonate \<22 mEq/L
• Liver disease (hepatic cirrhosis, alcohol/drug abuse ≥3 months, or serum AST, ALT, or total bilirubin \>3X the upper limit of normal)

Other

• Iodine intolerance
• Severe glaucoma
• Active pregnancy, breastfeeding or planning to become pregnant during study period
• Patient not able to understand and comply with study requirements, based on Investigator's judgment.

• Signed and dated written informed consent.
• Adult (≥18 years) at the time of consent
• Established T2D diagnosis as per Diabetes Canada
• HbA1c ≤10.0%
• eGFR ≥45 ml/min/1.73m2
• BP ≤160/90 and ≥90/60 mmHg
• BMI 18.5-45.0 kg/m2
• On stable dose of maximally tolerated RAASi for ≥30 days